2 enrolling by invitation. 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Enrolling by invitation 2 |
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy Biological: cizutamig - Immunoglobulin A Nephropathy (IgAN) | Early Phase 1 | Enrolling by invitation | Peking University First Hospital | 15 | 2025-07-16 | 2025-08-22 |
| The MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome. SCFA → Placebo (Sequence SP) and Placebo → SCFA (Sequence PS) - Primary IgA Nephropathy | Early Phase 1 | Enrolling by invitation | University Hospital, Martin | 120 | 2025-03-01 | 2026-08-06 |
Glomerulonephritis, IGA (2) · Renal Insufficiency, Chronic (1)
Autoimmune Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Immune System Diseases (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Nephritis (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Chronic Disease (1) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Renal Insufficiency (1)
Peking University First Hospital (1) · University Hospital, Martin (1)
China (1) · Slovakia (1)